International group scoops historic manufacturing site
Animal health company Zoetis has secured a historic manufacturing site in Melbourne’s most prominent biomedical research precinct from the Victorian government.
Csl
ASX 200 ends at record high
ASX 200 sets all-time high at close. Life360 soars 38 per cent on earnings beat. ASIC wants crime-linked Prospero wound up. China manufacturing activity better than expected but still weak.
Equal pay should lift productivity
It is in companies’ interests to pay staff fairly, regardless of gender.
CSL posts ‘strong’ result as plasma division delivers
An ‘exceptional’ performance from its plasma division has underpinned an uplift in first half profit with CSL reaffirming its full year growth outlook.
AGL’s Loy Yang hit by outage; ASX closes weaker
ASX 200 closes down 0.2pc at 7603.6points. Loy Yang A station offline. Callide C station failure report out. Macquarie hit by profit warning, star exit. Challenger lifts. Seek, Lew-backed Breville, Seven West and James Hardie fall.
ASX down as major drug trial scrapped
The Australian sharemarket fell on Monday after biotech giant CSL dropped its plans to continue with a major drug trial.
Heartbreak as CSL trial disappoints
The news was all bad for CSL when top-line results lobbed from its Phase 3 trial of a treatment to reduce the consequences of heart attacks.
CSL will still bet on blockbuster drugs
There were high hopes for a wonder drug being developed by CSL which failed. The pharma giant is still taking the win from the loss.
‘Herculean’ CSL drug trial falls flat
The biggest drug trial in CSL’s history, which sought to find a treatment for recurrent cardiac events, has failed to deliver the desired result.
CSL drags ASX lower; JB Hi-Fi gains
CSL weighs down market after disappointing cardiac drug trial. Fletcher halts for earnings guidance, CEO future update. Synlait sinks on earnings warning. Retailer JB Hi-Fi up as profit beats estimates.
Carbon capture needs to be more than just aspiration
To combat climate change we must use technology available to us now, such as removing CO2 from processing or industrial facilities, and burying it underground.
Quit RBA board, CSL directors told
Unions want CSL directors Carolyn Hewson and Alison Watkins to quit the RBA board due to CSL’s ‘corporate bastardry’.
Funds must put members first
Two powerful trade unions urging eight superannuation funds to review investment in Australia’s third-largest company, CSL, should stick to their day jobs.
Dump CSL, super funds told
Unions declare workers’ funds should not be used to finance CSL’s corporate bastardry.
Union plan to put boss in dock
CSL chief executive Paul McKenzie faces legal action after exposure of the company’s plan to cut workers’ pay.
ASX gains but post-CPI rally fades
RBA tipped to hold rates next week after inflation cools more than expected. Strong Harvey Norman protest vote as sales slow. Fisher & Paykel, CSL, Temple & Webster among gainers.
Revealed: CSL’s secret plan to cut pay, sack workers
Australia’s third biggest company devised a plan to shift workers on to lower pay and conditions and make them redundant if they refused to relocate.
The Ozempic effect
The weight loss drug is causing market value losses at healthcare leaders such as CSL and ResMed – but when will the market pay attention to the limits of what Ozempic may offer?
ASX 200 down; Treasury Wine gets first strike
Protest vote lodged against winemaker’s remuneration. Qantas down as oil prices jump, loyalty boss quits. Fletcher plunges on Iplex claims. Liontown hit with downgrades as Albemarle walks away.
CSL to feel the Bunsen burner over its Vifor acquisition
CSL’s falling share price on the back of the success of competitor Novo’s wonder-drug Ozempic is raising uncomfortable questions over its $18.2bn purchase of Vifor.
ASX ends down; CSL rebounds
Court finds ANZ failed to inform market over 2015 placement. China’s flat inflation signals need for stimulus. Fletcher Building dismisses BGC’s plumbing claims. Perpetual lifts. Pact rejects billionaire investor’s bid.
ASX ends flat; CSL tumbles to four-year low
CSL sinks past Covid lows. PwC former boss Luke Sayers tells Senate inquiry he feels terrible, but there were a ‘number of bad actor tax partners’. Tabcorp tanks. CBA tips ‘live’ RBA meeting. Redbubble soars.
‘We’re listening’: CSL avoids strike as investors vent
The third-largest company on the ASX narrowly avoided a first strike as investors took the biotechnology player to task on plans to award performance rights to the CEO.
ASX up; Rinehart ups Liontown stake
Gina Rinehart’s Hancock Prospecting has 19.9 per cent of Liontown. CSL avoids first strike. Profit fall, outlook weighs on BoQ. Qantas gains on chair exit.
Brokers splash upgrades on pool of stocks
Amid what seems like share market doom and gloom, brokers have a bright outlook on stocks across various sectors, including one with a 33 per cent upside.
ASX 200 rises despite energy falls
Low oil price hits Woodside, Santos. Lithium miners fall on JP Morgan downgrade. Union bid to expand IR laws. Trade surplus up more than expected. AUD gains.
ASX ends down; RBA keeps rates on hold
RBA holds rates at 4.1pc for fourth month. Inflation still too high: Bullock. US sale lifts Computershare. Avita tanks on new FDA hurdle. US, Aus bond yields hit new highs. Endeavour allows Wavish vote.
CSL’s ‘super flu jab’ gets a shot in the arm
Australia’s biggest health company has revealed its flu shot is 15pc more effective than conventional ones. But don’t expect the government to pay for it.
CSL inks deal with UK govt for 100m flu shots
Most people would groan at the thought of a future pandemic, but governments are determined not be caught out again, with the UK striking a new deal with CSL.
ASX falls; Goyder not leaving Qantas
Qantas objected to Qatar flights but not decision maker: Hudson. Virgin boss says government stance on Qatar flights shifted. ASX down as CSL, Star fall. RBA rate hold tipped post inflation data.
Original URL: https://www.theaustralian.com.au/topics/csl/page/2